Amgen 2010 Annual Report Download - page 6

Download and view the complete annual report

Please find page 6 of the 2010 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

AMG 386
Various cancer types
AMG 785
Bone-related conditions,
including postmenopausal
osteoporosis and fracture
healing
AMG 827
Infl ammatory diseases
AMG 853
Asthma
Conatumumab
Various cancer types
Denosumab
Rheumatoid arthritis
Ganitumab (AMG 479)
Various cancer types
Motesanib
First-line breast cancer
Nplate® (romiplostim)
Chemotherapy-induced
thrombocytopenia
Nplate®
Myelodysplastic syndromes
Omecamtiv mecarbil
(AMG 423)
Heart failure
Rilotumumab (AMG 102)
Various cancer types
Sensipar®/Mimpara®
(cinacalcet)
Post renal transplant
Vectibix® (panitumumab)
Locally advanced head and
neck cancer
AMG 386
Ovarian cancer
Aranesp® (darbepoetin alfa)
Anemia in heart failure
Ganitumab (AMG 479)
Pancreatic cancer
Motesanib
First-line non-small cell
lung cancer
Prolia® (denosumab)
Male osteoporosis
Sensipar®/Mimpara®
Cardiovascular disease
in patients with secondary
hyperparathyroidism and
chronic kidney disease
undergoing maintenance
dialysis
Vectibix®
First- and second-line
colorectal cancer
XGEVA™ (denosumab)
Prevention of bone metastases
in breast cancer
XGEVA™
Prevention of bone metastases
in prostate cancer
This chart shows selected clinical programs and molecules in Amgen’s development pipeline as of February 9, 2011, and is qualifi ed by the information presented in Amgen’s most recent Form 10-K,
which is included as part of this publication. Amgen’s product pipeline will change over time as programs and molecules move through the drug development process, including progressing to market
or failing in clinical trials, due to the nature of the development process, and Amgen disclaims any duty to update this information. For more information on our pipeline, visit www.amgen.com or refer
to Amgen’s most recent Form 10-K. For important safety information about Amgen’s approved, marketed, or commercially available medicines, visit www.amgen.com for links to the product websites.
Phase 1 Phase 2 Phase 3
AMG 139
Infl ammatory diseases
AMG 145
Hypercholesterolemia
AMG 151
Type 2 diabetes
AMG 157
Asthma
AMG 167
Bone-related conditions
AMG 181
Ulcerative colitis
AMG 191
Infl ammatory diseases
AMG 208
Various cancer types
AMG 221
Type 2 diabetes
AMG 319
Hematologic malignancies
AMG 337
Various cancer types
AMG 557
Systemic lupus erythematosus
AMG 745
Muscle-wasting disorders
AMG 747
Neuroscience
AMG 761
Asthma
AMG 780
Various cancer types
AMG 811
Systemic lupus erythematosus
AMG 820
Various cancer types
AMG 888
Various cancer types
AMG 900
Various cancer types
Dulanermin (rhApo2L/TRAIL)
Various cancer types
Amgen’s Pipeline—Using Science and Innovation
to Dramatically Improve People’s Lives
Modalities
Oral/Small
Molecule
Protein/
Peptibody
Antibody